유럽 연합 -
루마니아어 -
EMA (European Medicines Agency)
xalkori
pfizer europe ma eeig - crizotinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
루마니아 -
루마니아어 -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
xalkori
pfizer manufacturing deutschland gmbh - germania - crizotinibum - caps. - 200mg - inhibitori de protein-kinaza
루마니아 -
루마니아어 -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
xalkori
pfizer manufacturing deutschland gmbh - germania - crizotinibum - caps. - 250 mg - inhibitori de protein-kinaza